Human Reproduction Update Advance Access originally published online on September 26, 2008
Human Reproduction Update 2008 14(6):553-561; doi:10.1093/humupd/dmn041
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data
1 Department of Obstetrics and Gynecology, Ha'Emek Medical Center, Afula, Israel 2 Technion-Israel Institute of Technology, The Rappaport Faculty of Medicine, Haifa, Israel
3 Correspondence address. E-mail: shaleve{at}tx.technion.ac.il
BACKGROUND: Cancer survival rates in young women are improving due to progress in treatment. This includes aggressive chemotherapy, a treatment that often poses a threat to fertility. GnRH agonists were proposed as ovarian protectors during gonadotoxic therapies. This study was undertaken in order to determine the clinical evidence concerning this issue.
METHODS: The medical literature was searched for studies that reported on ovarian function after the administration of GnRH agonists concomitant with chemotherapy. Twelve studies met the predetermined selection criteria.
RESULTS: Data on ovarian function were obtained for 579 women who received chemotherapy. Among 345 women who received GnRH agonist co-treatment, ovarian function was preserved in 91% and 9% had premature ovarian failure. In 234 women who did not receive GnRH agonist co-treatment, ovarian function was preserved in 41% and failed in 59%. Only two of the studies were randomized. The control and the GnRH agonist groups differed in several important characteristics: the follow-up times were not equal, different treatment protocols were utilized and end-points were poorly defined and inconsistent between the studies.
CONCLUSIONS: The effectiveness of GnRH agonists as fertility-preserving agents is debatable. A thorough literature search has found insufficient evidence to show that GnRH agonist co-treatment is effective in protecting the ovary from the damage of chemotherapy. A large randomized controlled trial with adequate follow-up is needed.
Key words: female infertility / GnRH agonist / ovarian function
Received on November 26, 2007; revised June 30, 2008; accepted on August 11, 2008
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J. Lee, the ASCO Fertility Preservation Guidelines Committ, Z. Blumenfeld, K. Oktay, K. Rodriguez-Wallberg, L. Schover, B. M. Chubak, D. Meirow, W. H. Wallace, J. S. Jeruss, et al. Preservation of fertility in patients with cancer. N. Engl. J. Med., June 18, 2009; 360(25): 2680 - 2681. [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Hughes and M. S. Neal Ovulation suppression to protect against chemotherapy-induced ovarian toxicity: helpful or just hopeful? Hum. Reprod. Update, November 1, 2008; 14(6): 541 - 542. [Full Text] [PDF]
|
|